ATP7A

ATP7A is a gene that encodes a copper-transporting ATPase, crucial for regulating copper levels in the body and supporting vital biological processes like energy production and nervous system function. 

Mutations in ATP7A disrupt copper metabolism, leading to conditions such as Menkes disease, Occipital Horn Syndrome, and X-linked distal spinal muscular atrophy type 3, all of which are characterized by varying degrees of copper deficiency and neurological or connective tissue dysfunction.

What is ATP7A?

ATP7A is a gene that encodes a copper-transporting ATPase, which is a protein responsible for the proper regulation of copper levels in the body. This protein plays a role in incorporating copper into enzymes that are important for various biological processes, such as energy production, skin and connective tissue function, and the functioning of the nervous system. 

ATP7A is primarily expressed in the liver, brain, skin, intestines, and other tissues that require copper for normal function.

Clinical Implications of ATP7A Mutations

Mutations in ATP7A have been associated with various conditions:

ATP7A and Menkes Disease

Mutations in the ATP7A gene lead to a condition known as Menkes disease, a rare genetic disorder characterized by copper deficiency. This condition often manifests in infancy with symptoms such as developmental delay, brittle hair, poor muscle tone, and seizures. Without treatment, Menkes disease is typically fatal in early childhood due to severe neurological and organ dysfunction.

ATP7A and Occipital Horn Syndrome

ATP7A mutations can also cause a milder form of copper deficiency called Occipital Horn Syndrome (OHS), also known as cutis laxa. 

OHS is a milder variant of Menkes disease that typically presents between the ages of 5 to 10 years. It shares many features with classical Menkes, such as connective tissue abnormalities and bony abnormalities like exostoses on the occiput, but neurological symptoms are less severe. 

Intellectual disability and motor delays are present but less profound than in Menkes disease.

ATP7A and X-Linked Distal Spinal Muscular Atrophy Type 3

ATP7A mutations are primarily linked to copper metabolism disorders such as Menkes disease and Occipital Horn Syndrome, but they are also associated with X-linked distal spinal muscular atrophy type 3 (D-SMA3). 

In D-SMA3, mutations in the ATP7A gene lead to dysfunction of copper transport, affecting the nervous system. This results in progressive weakness and atrophy of distal muscles, particularly in the hands and feet. 

Unlike the more severe neurological defects seen in Menkes disease, D-SMA3 typically manifests later in life with motor weakness, and affected individuals may experience minimal sensory loss. The exact mechanism is linked to the disruption of copper-dependent enzymes in motor neurons, leading to their degeneration.

Who Should Get Tested for ATP7A Mutations?

Individuals who should be tested for ATP7A mutations include those with suspected Menkes disease (MD), Occipital Horn Syndrome (OHS), or X-linked distal spinal muscular atrophy type 3, particularly if they exhibit neurological symptoms, connective tissue abnormalities, or copper deficiency. 

Genetic testing is particularly important for patients with developmental delay, seizures, abnormal hair (e.g., kinky or sparse), or connective tissue deformities like hernias or joint laxity. 

Testing is also recommended for family members of affected individuals for carrier screening or prenatal diagnosis, especially in cases where de novo mutations are suspected.

Test Procedure and Interpretation

The following section outlines the typical test procedure and interpretation for ATP7A genetic testing:

Testing Procedure

ATP7A testing involves genetic testing, typically requiring blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for ATP7A genetic testing are considered to be without mutations that can alter the activity of the ATP7A proteins.

Clinical Implications of Positive ATP7A Mutations

The clinical implications of a positive ATP7A mutation test result will vary by individual, although ATP7A mutations in symptomatic patients signal an immediate need for further assessment and possibly treatment. 

Patients or practitioners with questions about the clinical implications of ATP7A mutations should seek further assessment with a genetic counselor or expert. 

Diagnostic Limitations

While ATP7A testing can provide valuable insights, it is important to interpret results carefully. The presence of ATP7A mutations should not be used in isolation for diagnosis. 

Clinicians must consider other biomarkers and clinical factors when making decisions about patient care. Additionally, sample handling and patient conditions can impact test results, so ensuring proper testing procedures is essential.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.